Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 24Neoplasms 10Fallopian Tube Neoplasms 7Breast Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 3Neoplasm Metastasis 2Mesothelioma 2Carcinoma, Transitional Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Neoplasms 1Urothelial Cancer 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma, Ewing 1Recurrence 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Pancreatic Adenocarcinoma 1Ovarian Diseases 1Mesothelioma, Malignant 1Melanoma 1Leukemia, Prolymphocytic, T-Cell 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Melanoma × niraparib × Clear all
NCT01294735 2012-08-15

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Merck Sharp & Dohme LLC

Phase 1 Completed
19 enrolled
CNSDermatologic

Glioblastoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡